trending Market Intelligence /marketintelligence/en/news-insights/trending/j5A06vSqSI3523HTB1bqZA2 content esgSubNav
In This List

Agios discontinues AG-519 drug development after FDA feedback

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Agios discontinues AG-519 drug development after FDA feedback

Agios Pharmaceuticals Inc. withdrew its investigational new drug application for its pyruvate kinase-R activator, AG-519, after a verbal notification of a clinical hold from the U.S. FDA.

The company has also discontinued development of the drug.

Agios said these decisions do not affect the ongoing global phase 2 study for AG-348, an activator of both wild-type and mutated pyruvate kinase-R enzymes, as a potential disease-modifying treatment for pyruvate kinase deficiency.

Pyruvate kinase deficiency is a rare, inherited disease that presents as hemolytic anemia, which is the accelerated destruction of red blood cells.